Drug Trial Radar · NCT01080391
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
792
Actual
Start
Jul 14, 2010
Primary completion
Jun 16, 2014
Study completion Dec 5, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Mar 4, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.
Conditions
- Relapsed Multiple Myeloma
Interventions
DexamethasoneDrug
40 mg orally or IV on days 1, 8, 15, 22
LenalidomideDrug
25 mg orally on days 1-21
CarfilzomibDrug
20 mg/m², 27 mg/m² intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
Locations
127 sites in 20 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
Providence St. Joseph Medical Center
Burbank, California
St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare
Santa Rosa, California
Stanford University
Stanford, California
Colorado Blood Cancer Institute
Denver, Colorado
Cancer and Blood Disease Center
Lecanto, Florida
Rush University Medical Center
Chicago, Illinois
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
University of Kansas Cancer Center
Kansas City, Kansas
The University of Michigan - Comprehensive Cancer Center
Ann Arbor, Michigan
Mayo Clinic
Rochester, Minnesota
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
NYU Clinical Cancer Center
New York, New York
Weill Cornell Medical College
New York, New York
Associates in Oncology and Hematology
Chattanooga, Tennessee
The Don & Sybil Harrington Cancer Center
Amarillo, Texas
Baylor Sammons Cancer Center
Dallas, Texas
UT Southwestern Medical Center at Dallas
Dallas, Texas
The University of Texas, MD Anderson Cancer Center
Houston, Texas
Scott and White Memorial Hospital
Temple, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin
Medizinische Universitat Wien
Vienna, Austria
Wilhelminspital der Stadt Wien, Zentrum fur Onkologie und Hamatologie
Vienna, Austria
Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg
Antwerp, Belgium
AZ Sint-Jan AV
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
UZ Brussel
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
University Multiprofile Hospital for Active Treatment, "Dr. Georgi Stranski"
Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment "Sveti Georgi"
Plovdiv, Bulgaria
Military Medical Academy Multiprofile Hospital for Active Treatment
Sofia, Bulgaria
Specialized Hospital for Active Treatment of Hematological Diseases
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment "Sveta Marina"
Varna, Bulgaria
Tom Baker Cancer Centre
Calgary, Alberta, Canada
University of Alberta, Cross Cancer Institute
Edmonton, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Cancer Care Manitoba
Winnipeg, Manitoba, Canada
General Hospital, Health Sciences Centre
St. John's, Newfoundland and Labrador, Canada
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.